Small molecule · Inhibitor of spleen tyrosine kinase (SYK) · developed by Hutchmed
Sovleplenib is an orally available inhibitor of spleen tyrosine kinase (SYK), a non-receptor tyrosine kinase associated with the B-cell receptor. By blocking SYK it inhibits B-cell receptor signaling, B-cell activation and tumor cell proliferation. It is studied in warm antibody autoimmune hemolytic anemia and primary immune thrombocytopenia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05535933 | Phase 2/3 | Warm Antibody Autoimmune Hemolytic Anemia | Active not recruiting | HCM |
| NCT05029635 | Phase 3 | Primary Immune Thrombocytopenia (ITP) | Completed | HCM |
| NCT07331194 | Phase 1 | Healthy | Completed | HCM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Warm Antibody Autoimmune Hemolytic AnemiaHealthyPrimary Immune Thrombocytopenia (ITP)
Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.
See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HCM catalysts and pipeline →